We describe the case of HIV-1 infected patient presenting to hospital with a severe cutaneous adverse drug reaction shortly after commencing dapsone therapy as Pneumocystis jirovecii pneumonia prophylaxis. To the best of our knowledge, acute generalised exanthematous pustulosis has not been reported as a reaction to dapsone in the setting of HIV.
BourkiaMCharlesLLambotteO. Life threatening acute generalized exanthematous pustulosis induced by two different protease inhibitors in an HIV-1 infected patient. J Antimicrob Chemother2011; 66(9): 2188–2189.
TohyamaMHashimotoKYasukawaM. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol2007; 157: 934–940.
CoopmanSJohnsonRPlattR. Cutaneous disease and drug reactions in HIV Infection. N Engl J Med1993; 328: 1670–1674.
7.
SmithKJSkeltonHGYeagerJ. Increased drug reactions in HIV-1 patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. The Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). Clin Exp Dermatol1997; 22(3): 118–123.
8.
SchmidSKuechlerPBritschgiM. Acute generalised exanthematous pustulosis. Role of cytotoxic T cells in pustule formation. Am J Pathol2002; 161: 2079–2086.
